ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2294

The Histone Deacetylase SIRT1 Is Anti-Fibrotic and Mediates Resveratrol Effects

Roberta G. Marangoni1, Archit Ghosh1, Jun Wei2 and John Varga3, 1Medicine, Rheumatolgoy, Northwestern University, Feinberg School of Medicine, Chicago, IL, 2Rheumatology Division, Northwestern University, Chicago, IL, 3Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Fibroblasts, scleroderma and transforming growth factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Fibrosis in scleroderma is associated with increased collagen synthesis driven by TGF-β and associated epigenetic modifications. The Class III histone deacetylase SIRT1 has anticancer and anti-inflammatory properties in vitro and in vivo, and its expression and activation are induced by the natural phytoalexin resveratrol. We investigated SIRT1 function and regulation by resveratrol during fibrogenesis.

Methods: SIRT1 expression in scleroderma skin biopsies was analyzed in published microarray dataset. The effects of resveratrol on fibrotic responses were evaluated by real-time qPCR, Western analysis, immunefluorescence, transient transfection, collagen gel contraction and cell migration assays. SIRT1 modulation of TGF-β signaling was examined using the pharmacological SIRT1 inhibitors splitomicin and nicotinamide. 

Results: Analysis of published microarray datasets revealed significant reduction of SIRT1 mRNA levels in skin biopsies from patients with diffuse cutaneous scleroderma n= 11, p<0.001). Resveratrol induced the activity of SIRT1 in explanted normal skin fibroblasts. Moreover, resveratrol blocked the stimulation of collagen gel contraction and cell migration induced by TGF-ß, and abrogated TGF-ß–induced collagen and α-smooth muscle actin expression, and Smad2/3-dependent transcriptional activity, in a dose-dependent manner. Ectopic SIRT1 by itself was sufficient to abrogate TGF-ß stimulated collagen expression, whereas pharmacological inhibition of SIRT prevented the anti-fibrotic activities of resveratrol.

Conclusion: Resveratrol abrogates canonical TGF-β signaling and suppresses fibrotic responses via the histone deacetylase and essential metabolic regulator SIRT1. Reduction of SIRT1 in scleroderma skin biopsies suggests its role in regulating fibrogenesis.  Accordingly, we propose that SIRT1 is a novel target for anti-fibrotic therapy, and pharmacological enhancement of the SIRT1 expression or activity might have a therapeutic potential in scleroderma.


Disclosure:

R. G. Marangoni,
None;

A. Ghosh,
None;

J. Wei,
None;

J. Varga,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-histone-deacetylase-sirt1-is-anti-fibrotic-and-mediates-resveratrol-effects/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology